Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kelly Schick Insider Profile
4 Followers
Kelly Schick, CHRO at Amag Pharmaceuticals, holds 56.49K shares in C4 Therapeutics (Ticker: CCCC), holds 0.00 shares in Amag Pharmaceuticals (Ticker: AMAG).
Kelly Schick Amag Pharmaceuticals (AMAG)CHRO
Amag Pharmaceuticals (AMAG)
CHRO
Not Ranked
Kelly Schick has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CPO
Roles that Kelly Schick holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kelly Schick
Kelly Schick's Trading History
Amag Pharmaceuticals
Nov 17, 2020
―
Uninformative Sell
―
$0.00
C4 Therapeutics
Nov 12, 2024
CPO
Uninformative Buy
15.99K
$223.13K
List of latest transactions for each holding click on a transaction to see Kelly Schick's performance on stock
You May Also Like
Kelly Schick insider profile FAQ
What is the percentage of profitable transactions made by Kelly Schick?
The percentage of profitable transactions made by Kelly Schick is ―.
What is the average return per transaction made by Kelly Schick?
The average return per transaction made by Kelly Schick is ―.
What stocks does Kelly Schick hold?
Kelly Schick holds: AMAG, CCCC stocks.
What was Kelly Schick’s latest transaction?
Kelly Schick latest transaction was an Uninformative Buy of $15.99K.
What was Kelly Schick's most profitable transaction?
Kelly Schick’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kelly Schick's role in Amag Pharmaceuticals?
Kelly Schick's role in Amag Pharmaceuticals is CHRO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.